In a small phase II study, the clinical activity of BV in R/R EBV+ and CD30+ non-Hodgkin lymphomas (22 mature NK/T cell and 3 mature B-cell lymphoma cases) was substantial and durable, with an ORR of 48% and a duration of response of 10.1 months, suggesting BV as a promising therapy for patients with EBV+ DLBCL [91]. Here, TNFRSF8 is linked to B-cell non-Hodgkin lymphoma.